LV Fibroma vs Rhabdomyoma

Echo-focused differentiating points 👉:

Rhabdomyoma: Usually multiple, homogeneous echogenic masses, intramyocardial, no calcification, often in infants, tendency to regress.

Fibroma: Typically solitary, very bright echogenic mass with shadowing due to calcification, well-circumscribed, often larger, does not regress, commonly in LV free wall or septum.

To confirm LV fibroma vs rhabdomyoma, the key modality is Cardiac MRI — echo alone cannot definitively distinguish them. Here’s the clean, practical approach used clinically:

---

✅ How to Confirm LV Fibroma vs Rhabdomyoma

1. Cardiac MRI (Gold Standard)

Rhabdomyoma

T1: Iso / mildly hyperintense

T2: Hyperintense

LGE: No or minimal enhancement

Often multiple lesions

Fibroma

T1: Hypointense

T2: Hypointense

LGE: Intense, central enhancement (classic “bright core”)

Well-defined, usually solitary

→ Pattern of LGE is the single best differentiator.

---

2. Clinical Clues

Rhabdomyoma

Infant with multiple masses

Features of Tuberous sclerosis

Tumor shrinking on follow-up scan

Fibroma

Older child

Solitary, large LV wall mass

Ventricular arrhythmias (common)

---

3. Follow-up Imaging

Rhabdomyoma decreases over months

Fibroma stays same or increases → confirms fibrotic tumor

---

4. Genetic / Syndromic Workup

If rhabdomyoma suspected → Tuberous sclerosis evaluation (TSC1/TSC2)

Fibroma has no strong genetic link

---

5. Histology (rarely needed)

Only if diagnosis unclear or mass causing severe symptoms

Surgery + biopsy mainly for fibroma

---

⭐ Practical Rule

If MRI shows strong central LGE → fibroma.

If MRI shows no LGE and multiple lesions → rhabdomyoma.

Comments

Brugada ECG vs Incomplete Right Bundle Branch Block (iRBBB)

Brugada ECG vs Incomplete Right Bundle Branch Block (iRBBB) Why this differentiation matters Brugada pattern is a malignant channelopathy associated with sudden cardiac death, while incomplete RBBB is usually a benign conduction variant. Mislabeling Brugada as iRBBB can be fatal; overcalling iRBBB as Brugada can lead to unnecessary anxiety and ICD implantation. --- 1. Basic Definitions Brugada ECG Pattern Primary repolarization abnormality Genetic sodium-channel disorder Characteristic ST-segment elevation in V1–V3 Risk of ventricular fibrillation and sudden death Incomplete RBBB (iRBBB) Depolarization abnormality Delay in right ventricular conduction Common in healthy individuals Usually asymptomatic and benign --- 2. ECG Morphology: Side-by-Side Comparison QRS Duration Brugada: QRS usually <120 ms iRBBB: QRS <120 ms, but with RBBB morphology --- V1–V2 Pattern (Key Differentiator) Brugada Pseudo-RBBB appearance ST elevation ≥2 mm ST segment is coved or saddleback Terminal QRS bl...

Acute Treatment of Hyperkalemia

Acute Treatment of Hyperkalemia – A Practical, Bedside-Oriented Guide Hyperkalemia is a potentially life-threatening electrolyte abnormality that demands prompt recognition and decisive management. The danger lies not only in the absolute potassium value but in its effects on cardiac conduction, which can rapidly progress to fatal arrhythmias. Acute treatment focuses on three parallel goals: stabilizing the cardiac membrane, shifting potassium into cells, and removing excess potassium from the body. Understanding this stepwise approach helps clinicians act quickly and rationally in emergency settings. Why Hyperkalemia Is Dangerous Potassium plays a key role in maintaining the resting membrane potential of cardiac myocytes. Elevated serum potassium reduces the transmembrane gradient, leading to slowed conduction, ECG changes, ventricular arrhythmias, and asystole. Importantly, ECG changes do not always correlate with potassium levels, so treatment decisions should be based on clinical c...

𝘼𝙣𝙩𝙞𝙘𝙤𝙖𝙜𝙪𝙡𝙖𝙩𝙞𝙤𝙣 𝘼𝙛𝙩𝙚𝙧 𝙎𝙩𝙧𝙤𝙠𝙚

𝘼𝙣𝙩𝙞𝙘𝙤𝙖𝙜𝙪𝙡𝙖𝙩𝙞𝙤𝙣 𝘼𝙛𝙩𝙚𝙧 𝙎𝙩𝙧𝙤𝙠𝙚 in Patient with AF and acute IS/TIA European Heart Association Guideline recommends: • 1 days after TIA • 3 days after mild stroke • 6 days after moderate stroke • 12 days after severe stroke Early anticoagulation can decrease a risk of recurrent stroke and embolic events but may increase a risk of secondary hemorrhagic transformation of brain infarcts. The 1-3-6-12-day rule is a known consensus with graded increase in delay of anticoagulation between 1 and 12 days after onset of ischemic stroke or transient ischemic attack(TIA), according to neurological severity based on European expert opinions. However, this rule might be somewhat later than currently used in a real-world practical setting.

Dr. Usman's Cardiology Notes

Search This Blog